Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?

[1]  M. Lalu,et al.  Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval—FASTER Approval , 2022, Stem cells translational medicine.

[2]  M. Kiso,et al.  Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters , 2022, Nature Microbiology.

[3]  Shinji Watanabe,et al.  Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 , 2022, The New England journal of medicine.

[4]  J. Makarem,et al.  Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II , 2022, Stem cell research & therapy.

[5]  D. Annane,et al.  Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial , 2022, Critical Care.

[6]  A. Lam,et al.  Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. , 2022, Cytotherapy.

[7]  Kuan-Han Chen,et al.  The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review , 2022, Human vaccines & immunotherapeutics.

[8]  D. Allan,et al.  Mesenchymal stem/stromal cell–based therapies for COVID-19: First iteration of a living systematic review and meta-analysis , 2022, Cytotherapy.

[9]  R. Petterle,et al.  Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial , 2021, Stem Cell Research & Therapy.

[10]  J. Casanova,et al.  Mechanisms of viral inflammation and disease in humans , 2021, Science.

[11]  Lian Yang,et al.  Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan , 2021, Infectious Diseases and Therapy.

[12]  F. Baldanti,et al.  Antibody therapy for COVID-19 , 2021, Current opinion in allergy and clinical immunology.

[13]  D. Allan,et al.  Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol , 2021, Systematic Reviews.

[14]  A. Naguib,et al.  Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial , 2021, The American journal of tropical medicine and hygiene.

[15]  Arthur Taylor,et al.  Mesenchymal stromal cells: what have we learned so far about their therapeutic potential and mechanisms of action? , 2021, Emerging topics in life sciences.

[16]  R. Xu,et al.  Mesenchymal stem cell therapy for severe COVID-19 , 2021, Signal Transduction and Targeted Therapy.

[17]  M. Andreef,et al.  Sulfated Alginate Hydrogels Prolong the Therapeutic Potential of MSC Spheroids by Sequestering the Secretome , 2021, Advanced healthcare materials.

[18]  G. Úrrutia,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. , 2021, Revista espanola de cardiologia.

[19]  S. Yavuz,et al.  An update of anti-viral treatment of COVID-19 , 2021, Turkish journal of medical sciences.

[20]  Leora I. Horwitz,et al.  Six-Month Outcomes in Patients Hospitalized with Severe COVID-19 , 2021, Journal of General Internal Medicine.

[21]  E. Holmes,et al.  After the pandemic: perspectives on the future trajectory of COVID-19 , 2021, Nature.

[22]  F. Zhao,et al.  Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19 , 2021, NPJ Regenerative medicine.

[23]  I. Liem,et al.  Umbilical cord mesenchymal stromal cells as critical COVID‐19 adjuvant therapy: A randomized controlled trial , 2021, Stem cells translational medicine.

[24]  Zhipeng Yan,et al.  COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials , 2021, Pharmaceuticals.

[25]  Engy Elekhnawy,et al.  Present and future treatment strategies for coronavirus disease 2019 , 2021, Future Journal of Pharmaceutical Sciences.

[26]  K. Akarid,et al.  The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? , 2021, Microbial Pathogenesis.

[27]  D. Pei,et al.  Challenges and advances in clinical applications of mesenchymal stromal cells , 2021, Journal of Hematology & Oncology.

[28]  S. Agarwal,et al.  COVID-19: Characteristics and Therapeutics , 2021, Cells.

[29]  A. Marttos,et al.  Umbilical cord mesenchymal stem cells for COVID‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial , 2021, Stem cells translational medicine.

[30]  E. Karaoz,et al.  The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial , 2021, Cell transplantation.

[31]  T. Minko,et al.  Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 , 2021, The AAPS journal.

[32]  Liu Wang,et al.  Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis , 2020, Cell proliferation.

[33]  R. Xu,et al.  Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial , 2020, Signal Transduction and Targeted Therapy.

[34]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[35]  Seyyed Mahmoud Hashemi,et al.  Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action , 2020, Life Sciences.

[36]  D. Qi,et al.  Corticosteroid therapy for patients with severe novel Coronavirus disease 2019. , 2020, European review for medical and pharmacological sciences.

[37]  Z. Qian,et al.  Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 , 2020, Stem Cell Research & Therapy.

[38]  D. Allan,et al.  Human endothelial colony‐forming cells in regenerative therapy: A systematic review of controlled preclinical animal studies , 2020, Stem cells translational medicine.

[39]  Ashish Kumar,et al.  Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region , 2020, medRxiv.

[40]  J. Karp,et al.  Shattering barriers toward clinically meaningful MSC therapies , 2020, Science Advances.

[41]  A. Drilon,et al.  An umbrella approach to test lung cancer therapies , 2020, Nature.

[42]  D. Allan,et al.  A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence—FAST Evidence , 2020, Transfusion Medicine Reviews.

[43]  Shaoying Huang,et al.  The cytokine storm and COVID‐19 , 2020, Journal of medical virology.

[44]  Mathias Uhlen,et al.  Current Status of COVID-19 Therapies and Drug Repositioning Applications , 2020, iScience.

[45]  C. Ruiz,et al.  SARS-CoV-2 infection: The role of cytokines in COVID-19 disease , 2020, Cytokine & Growth Factor Reviews.

[46]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[47]  L. Amorosa,et al.  An Update on Current Therapeutic Drugs Treating COVID-19 , 2020, Current Pharmacology Reports.

[48]  Eleanor M. Rees,et al.  COVID-19 length of hospital stay: a systematic review and data synthesis , 2020, BMC Medicine.

[49]  R. Bhatia,et al.  Impact of COVID-19 pandemic on health system & Sustainable Development Goal 3 , 2020, The Indian journal of medical research.

[50]  Changming Niu,et al.  Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells , 2020, Stem Cell Research & Therapy.

[51]  I. Martin,et al.  Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential , 2020, Cytotherapy.

[52]  A. Ardeshirylajimi,et al.  Mesenchymal Stem Cell Therapy for COVID-19: Present or Future , 2020, Stem Cell Reviews and Reports.

[53]  Heng Li,et al.  Coronavirus disease 2019 (COVID-19): current status and future perspectives , 2020, International Journal of Antimicrobial Agents.

[54]  Weidong Wu,et al.  Virology, Epidemiology, Pathogenesis, and Control of COVID-19 , 2020, Viruses.

[55]  Dae-Gyun Ahn,et al.  Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) , 2020, Journal of microbiology and biotechnology.

[56]  Jay J H Park,et al.  An overview of precision oncology basket and umbrella trials for clinicians , 2020, CA: a cancer journal for clinicians.

[57]  P. Trikha,et al.  Editorial: Current Perspectives, Challenges and Advances in Cell Based Therapies , 2020, Frontiers in Oncology.

[58]  Jianyong Xu,et al.  Immune modulation by mesenchymal stem cells , 2019, Cell proliferation.

[59]  I. Martin,et al.  Mesenchymal stem versus stromal cells: International Society for Cellular Therapy Mesenchymal Stromal Cell committee position statement on nomenclature. , 2019, Cytotherapy.

[60]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[61]  Paul J Catalano,et al.  Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices , 2019, Journal of the National Cancer Institute.

[62]  M. Dahlke,et al.  Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs , 2019, Front. Immunol..

[63]  Karl Broich,et al.  Master protocols in clinical trials: a universal Swiss Army knife? , 2019, The Lancet. Oncology.

[64]  L. Cancio,et al.  Preconditioning in an Inflammatory Milieu Augments the Immunotherapeutic Function of Mesenchymal Stromal Cells , 2019, Cells.

[65]  Yeong-Hoon Choi,et al.  Preconditioning of bone marrow-derived mesenchymal stem cells highly strengthens their potential to promote IL-6-dependent M2b polarization , 2018, Stem Cell Research & Therapy.

[66]  Tianjing Li,et al.  Network meta-analysis: an introduction for clinicians , 2017, Internal and Emergency Medicine.

[67]  M. León-Juárez,et al.  Inflammasomes and its importance in viral infections , 2016, Immunologic research.

[68]  V. Ogay,et al.  Preconditioning of Human Mesenchymal Stem Cells to Enhance Their Regulation of the Immune Response , 2016, Stem cells international.

[69]  M. Cheung,et al.  A Guide to Conducting a Meta-Analysis , 2016, Neuropsychology Review.

[70]  J. Hyllner,et al.  Cell-based therapy technology classifications and translational challenges , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[71]  Aaron D. Levine,et al.  Challenges in the translation and commercialization of cell therapies , 2015, BMC Biotechnology.

[72]  J. Ioannidis,et al.  Small studies are more heterogeneous than large ones: a meta-meta-analysis. , 2015, Journal of clinical epidemiology.

[73]  Bruno R. da Costa,et al.  Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. , 2014, European heart journal.

[74]  J. Karp,et al.  Mesenchymal stem cells: immune evasive, not immune privileged , 2014, Nature Biotechnology.

[75]  R. Puri,et al.  MSC-based product characterization for clinical trials: an FDA perspective. , 2014, Cell stem cell.

[76]  Mehmet Fatih Yanik,et al.  mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. , 2013, Blood.

[77]  Rebecca M. Turner,et al.  The Impact of Study Size on Meta-analyses: Examination of Underpowered Studies in Cochrane Reviews , 2013, PloS one.

[78]  T. Ritter,et al.  Anti‐donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? , 2013, Immunology and cell biology.

[79]  Mike W-L Cheung,et al.  Conducting a meta‐analysis: basics and good practices , 2012, International journal of rheumatic diseases.

[80]  E. Wiertz,et al.  Exploitation of Herpesvirus Immune Evasion Strategies to Modify the Immunogenicity of Human Mesenchymal Stem Cell Transplants , 2011, PloS one.

[81]  S. Reich-Zeliger,et al.  Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells , 2009, Stem cells.

[82]  L. Lejeune,et al.  Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. , 2005, Blood.

[83]  Frank P Barry,et al.  Mesenchymal stem cells avoid allogeneic rejection , 2005, Journal of Inflammation.

[84]  F. Barry,et al.  Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. , 2005, Stem cells and development.

[85]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[86]  F. Aerts-Kaya,et al.  Use of Mesenchymal Stem Cells in COVID-19 , 2020 .

[87]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.